REPLIGEN CORP RGEN
References throughout this Form 10-K to "Repligen Corporation", "Repligen", "we", "us", "our", or the "Company" refer to Repligen Corporation and its subsidiaries, taken as a whole, unless the context otherwise indicates.
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs.
As the overall market for biologics continues to grow and expand, our primary customers – global biopharmaceutical companies, contract development and manufacturing organizations and other life science companies (integrators) – face critical production cost, capacity, quality and time pressures. Built to address these concerns, our products help set new standards for the way biologics are manufactured. We are committed to inspiring advances in bioprocessing as a trusted partner in the production of critical biologic drugs – including monoclonal antibodies ("mAbs") and mAb derivatives like antibody drug conjugates, recombinant proteins, RNA-based therapeutics and vaccines and cell and gene therapies ("C>") – that are improving human health worldwide.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $738.3M | $634.4M | $632.4M | $801.5M | $670.5M | $366.3M | $270.2M | $194.0M | $141.2M | $104.5M |
| Cost of revenue | $352.0M | $359.8M | $353.9M | $345.8M | $279.3M | $156.6M | $119.1M | $86.5M | $67.0M | $47.1M |
| Gross profit | $386.2M | $274.6M | $278.4M | $455.7M | $391.3M | $209.6M | $151.1M | $107.5M | $74.2M | $57.4M |
| R&D | $54.2M | $43.2M | $42.7M | $43.9M | $34.3M | $20.2M | $19.4M | $15.8M | $8.7M | $7.4M |
| SG&A | $290.5M | $263.4M | $218.6M | $215.8M | $183.9M | $119.6M | $95.6M | $65.7M | $51.5M | $30.9M |
| Total operating expenses | $683.1M | $669.6M | $584.7M | $576.9M | $503.3M | $296.4M | $234.2M | $168.0M | $127.2M | $88.6M |
| Operating income | $55.2M | -$35.1M | $47.7M | $224.7M | $167.2M | $69.8M | $36.1M | $26.0M | $14.0M | $16.0M |
| Interest expense | $21.5M | $20.7M | $2.5M | $1.2M | $11.3M | $10.8M | $9.3M | $6.7M | $6.4M | $3.8M |
| Pre-tax income | $62.4M | -$27.0M | $56.7M | $219.1M | $153.5M | $59.2M | $26.2M | $21.4M | $7.2M | $11.7M |
| Income tax | $13.5M | $1.5M | $21.1M | $33.2M | $25.3M | $709.0K | $4.7M | $4.8M | $21.1M | $11.0K |
| Net income | $48.9M | -$25.5M | $35.6M | $186.0M | $128.3M | $59.9M | $21.4M | $16.6M | $28.4M | $11.7M |
| EPS, basic | 0.87 | -0.46 | 0.64 | 3.35 | 2.33 | 1.14 | 0.44 | 0.38 | 0.74 | 0.35 |
| EPS, diluted | 0.86 | -0.46 | 0.63 | 3.24 | 2.24 | 1.11 | 0.44 | 0.37 | 0.72 | 0.34 |
| Shares, diluted (wtd. avg.) | $56.6K | $55.9K | $56.4K | $57.5K | $57.3K | $53.9K | $49.2M | $45.5M | $39.1M | $34.1K |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $566.0M | $757.4M | $751.3M | $523.5M | $603.8M | $717.3M | $537.4M | $193.8M | $173.8M | $122.7M |
| Short-term investments | $201.6M | $0 | — | — | — | — | — | $0 | $0 | — |
| Receivables | $158.6M | $134.1M | $124.2M | $116.2M | $117.4M | $71.4M | $43.1M | $33.0M | $27.6M | $15.2M |
| Inventory | $170.5M | $143.0M | $202.3M | $238.3M | $184.5M | $95.0M | $54.8M | $42.3M | $39.0M | $24.7M |
| Total current assets | $1.14B | $1.07B | $1.11B | $998.1M | $931.7M | $902.4M | $641.8M | $275.7M | $242.8M | $184.2M |
| Property, plant and equipment | $186.6M | $197.7M | $207.4M | $190.7M | $125.0M | $66.9M | $48.5M | $32.2M | $22.4M | $15.0M |
| Goodwill | $1.11B | $1.03B | $987.1M | $855.5M | $860.4M | $618.3M | $468.4M | $326.7M | $327.3M | $59.5M |
| Other intangibles | $386.1M | $397.9M | $407.0M | $360.6M | $337.3M | $287.1M | $212.6M | $135.4M | $144.8M | $29.8M |
| Total assets | $2.95B | $2.83B | $2.83B | $2.53B | $2.36B | $1.90B | $1.40B | $774.6M | $743.5M | $288.9M |
| Accounts payable | $30.0M | $32.1M | $19.6M | $27.6M | $36.2M | $16.9M | $11.4M | $10.5M | $7.3M | $5.1M |
| Total current liabilities | $135.8M | $126.8M | $164.9M | $404.2M | $375.3M | $319.0M | $48.3M | $129.8M | $25.2M | $21.1M |
| Long-term debt | $542.2M | $525.6M | — | — | — | — | — | — | — | — |
| Total liabilities | $843.6M | $856.9M | $866.3M | $620.9M | $608.3M | $373.7M | $340.3M | $159.1M | $152.0M | — |
| Retained earnings | $456.2M | $407.4M | $432.9M | $397.3M | $194.1M | $65.8M | $5.8M | -$677.0K | -$31.5M | -$59.9M |
| Total equity | $2.11B | $1.97B | $1.96B | $1.91B | $1.75B | $1.53B | $1.06B | $615.6M | $591.5M | $168.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $117.4M | $175.4M | $113.9M | $172.1M | $119.0M | $62.6M | $67.2M | $32.8M | $17.5M | $7.5M |
| Depreciation and amortisation | $39.7M | $35.0M | $37.0M | $23.9M | $16.4M | $10.9M | $7.3M | $5.2M | $4.2M | $3.3M |
| Stock-based compensation | $32.6M | $48.1M | $25.6M | $27.3M | $27.5M | $17.0M | $12.8M | $10.2M | $6.7M | $4.6M |
| Capital expenditure | $23.5M | $25.7M | $36.2M | $84.8M | $67.1M | $22.5M | $18.5M | $10.6M | $5.5M | $4.3M |
| Investing cash flow | -$298.5M | -$86.4M | -$123.3M | -$233.2M | -$221.2M | -$201.4M | -$205.3M | -$14.0M | -$98.7M | -$49.2M |
| Financing cash flow | -$15.2M | -$82.9M | $249.0M | -$13.3M | $961.0K | $305.9M | $484.9M | $3.4M | $129.9M | $112.1M |
| Buybacks | $0 | $0 | $14.4M | $0 | $0 | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-076528.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |